
This article was downloaded by: [USC University of Southern California] On: 13 March 2015, At: 06:07 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn20

## Aryl-Containing Esters Of Triphosphoric Acid As Substrates Of Terminal Deoxynucleotidyl Transferase

A. L. Khandazhinskaya<sup>a</sup>, E. S. Matyugina<sup>a</sup>, L. A. Alexandrova<sup>a</sup>, E. A. Shirokova<sup>a</sup>, M. K. Kukhanova<sup>a</sup> & M. V. Jasko<sup>a</sup> <sup>a</sup> Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Published online: 10 Dec 2007.

To cite this article: A. L. Khandazhinskaya , E. S. Matyugina , L. A. Alexandrova , E. A. Shirokova , M. K. Kukhanova & M. V. Jasko (2007) Aryl-Containing Esters Of Triphosphoric Acid As Substrates Of Terminal Deoxynucleotidyl Transferase, Nucleosides, Nucleotides and Nucleic Acids, 26:6-7, 641-644, DOI: <u>10.1080/15257770701490480</u>

To link to this article: <u>http://dx.doi.org/10.1080/15257770701490480</u>

### PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>



#### ARYL-CONTAINING ESTERS OF TRIPHOSPHORIC ACID AS SUBSTRATES OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE

A. L. Khandazhinskaya, E. S. Matyugina, L. A. Alexandrova, E. A. Shirokova,

**M. K. Kukhanova, and M. V. Jasko** *Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia* 

□ A new group of terminal deoxynucleotidyltransferase (TDT) substrates, namely, non-nucleoside triphosphates (NNTP) bearing 5-substituted 2,4-dinitrophenyl fragments instead of nucleoside residues was synthesized.

Keywords Non-nucleoside triphosphates; terminal deoxynucleotidyltransferase

#### INTRODUCTION


Terminal deoxynucleotidyltransferase (TDT, EC 2.7.7.31) is a unique template-independent DNA polymerase. TDT belongs to the X polymerase family, a subclass of an ancient nucleotidyltransferase superfamily, which includes nucleic acid polymerases such as DNA polymerases  $\beta$ ,  $\lambda$ ,  $\mu$ , and some others. Unlike any other DNA polymerases, TDT incorporates both ribo- and deoxyribonucleotides in vitro with the equal efficacy as well as a large array of unnatural nucleoside triphosphates. It was shown in our laboratory that thriphosphate analogues bearing different bulky alkyl and aryl groups instead of a nucleoside residue can serve as substrates for calf thymus TDT, thus, demonstrating that the presence of a nucleic base in the substrate molecule is not a determining factor for the binding to the enzyme active site and incorporation into the growing DNA chain.<sup>[1-3]</sup> The efficacy of these compounds depends on substituent and linker structures and length.<sup>[4,5]</sup> It was shown that the affinities of some of the compounds of this series towards TDT were similar to those of natural substrates. Moreover, non-nucleoside triphosphates (NNTP) were demonstrated to be inhibitors and/or substrate terminators of other polymerases of the X family, particularly, of human  $\beta$  and  $\lambda$  polymerases.<sup>[6]</sup>

The work was supported by the Russian Foundation for Basic Research, project No. 06-04-48248.

Address correspondence to A.L. Khandazhinskaya, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov str., Moscow, 119991 Russia. E-mail: lhba-imb@mail.ru


#### **RESULTS AND DISCUSSION**

We present in this work the synthesis of new NNTPs of the following structures:



Ia: n=2, R=F; Ib: n=2, R=Im; Ic: n=2, R=H; IIa: n=4, R=F; IIb: n=4, R=Im; IIc: n=4, R=H

Compounds (IIIa, IIIc, IVa, and IVc) were obtained by the reaction of the corresponding aminoalcohol with 1,3-difluoro-4,6-dinitrobenzene (for IIIa and IVa) or 1-fluoro-2,4-dinitrobenzene (for IIIc and IVc). For the preparation of the imidazole derivative (IIIb and IVb), the corresponding fluoro-containing precursors were treated with a solution of imidazole in DMF. The Ludwig triphosphorylation<sup>[7]</sup> carried out without the isolation of intermediate monophosphates gave the target triphosphates (Scheme).



The synthesized fluoro-containing triphosphates proved to be rather labile under the conditions of ion-exchange chromatography on DEAE (HCO<sub>3</sub><sup>-</sup>-form), and, therefore, were isolated in the following way. The reaction mixture was diluted with water and passed through a Dowex  $50^{(H+)}$  column. The resulting solution was concentrated, and the target product was purified on a reversed-phase LiChroprep RP-18 column. Total yields of the synthesized triphosphates achieved 15–30% from the starting amino alcohol.

All the synthesized compounds demonstrated potent substrate properties in cell-free experiments with TDT.<sup>[8]</sup>

#### **EXPERIMENTAL SECTION**

**N**-(2,4-Dinitro-5-fluorophenyl)-2-aminoethyl triphosphate Ia. Yield 21%. UV (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  265 nm (ε 9000), 349 nm (ε 15900). <sup>1</sup>H-NMR (D<sub>2</sub>O): 9.10 (1H, d, *J* 8.1, H3), 7.04 (1H, d, *J* 14.6, H6), 4.22 (2H, dt, CH<sub>2</sub>), 3.75 (2H, t, *J* 5.3, CH<sub>2</sub>N). <sup>31</sup>P-NMR (D<sub>2</sub>): -5.72 (1P, d, *J* 20.3, P<sub>γ</sub>), -10.39 (1P, d, *J* 19.3, P<sub>α</sub>), -21.50 (1P, dd, P<sub>β</sub>). Mass (m/e): 484.1 [M<sup>+</sup>-1].

**N-(2,4-Dinitro-5-imidazolylphenyl)-2-aminoethyl triphosphate Ib.** Yield 17%. UV (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  272 nm ( $\varepsilon$  5800), 365 nm ( $\varepsilon$  7000) <sup>1</sup>H-NMR (D<sub>2</sub>O): 9.24 (1H, s, H3), 8.96, 7.67 and 7.55 (3H, 3 br.s, Im), 7.50 (1H, s, H6), 4.40 (2H, m, CH<sub>2</sub>), 3.83 (2H, t, *J* 5.3, CH<sub>2</sub>N). <sup>31</sup>P-NMR (D<sub>2</sub>): -10.24 (1P, d, *J* 19.3, P<sub> $\gamma$ </sub>), -10.83 (1P, d, *J* 20.3, P<sub> $\alpha$ </sub>), -22.61 (1P, dd, P<sub> $\beta$ </sub>). Mass (m/e): 532.2 [M<sup>+</sup>-1].

**N-(2,4-Dinitrophenyl)-2-aminoethyl triphosphate Ic.** Yield 24%. UV-VIS (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  265 nm ( $\varepsilon$  8300), 363 nm ( $\varepsilon$  17500). <sup>1</sup>H-NMR (D<sub>2</sub>O): 8.95 (1H, d, *J*2.5, H3), 8.23 (3H, dd, -5), 7.21 (1H, d, *J*9.65, H6), 4.01 (2H, m, CH<sub>2</sub>), 3.72 (2H, t, *J* 5.9, CH<sub>2</sub>N).<sup>31</sup>P NMR (D<sub>2</sub>O):  $\delta$  -9.88 (d, 1P, *J* 21.4, P<sub> $\nu$ </sub>), -10.32 (d, 1P, *J* 19.3, P<sub> $\alpha$ </sub>), -21.77 (dd, 1P, P<sub> $\beta$ </sub>). Mass (m/e): 466.1 [M<sup>+</sup>-1].

**N-(2,4-Dinitro-5-fluorophenyl)-4-aminobutyl** triphosphate IIa. Yield 15%. UV (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  265 nm (ε 9100), 349 nm (ε 16000).<sup>1</sup>H-NMR (D<sub>2</sub>O): 9.10 (1H, d, *J* 8.1, H3), 6.94 (1H, d, *J* 15.6, H6), 4.01 (2H, m, CH<sub>2</sub>), 3.50 (2H, t, *J* 6.8, CH<sub>2</sub>N), 1.77 (4, m, (CH<sub>2</sub>)<sub>2</sub>). <sup>31</sup>P-NMR (D<sub>2</sub>): -10.12 (1P, d, *J* 19.3, P<sub>γ</sub>), -10.32 (1P, d, *J* 20.3, P<sub>α</sub>), -22.65 (1P, dd, P<sub>β</sub>). Mass (m/e): 512.1 [M<sup>+</sup>-1].

**N-(2,4-Dinitro-5-imidazolylphenyl)-4-aminobutyl triphosphate IIb.** Yield 23%. UV (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  272 nm ( $\varepsilon$  5800), 365 nm ( $\varepsilon$  7000).<sup>1</sup>H-NMR (D<sub>2</sub>O): 9.19 (1H, s, H3), 8.30, 7.45 and 7.33 (3H, 3 br.s, Im), 7.19 (1H, s, H6), 3.99 (2H, m, CH<sub>2</sub>), 3.54 (2H, t, *J* 6.8, CH<sub>2</sub>N), 1.82-1.72 (4, m, (CH<sub>2</sub>)<sub>2</sub>). <sup>31</sup>P-NMR (D<sub>2</sub>): -10.10 (1P, d, *J* 19.3, P<sub> $\gamma$ </sub>), -10.31 (1P, d, *J* 20.3, P<sub> $\alpha$ </sub>), -22.64 (1P, dd, P<sub> $\beta$ </sub>). Mass (m/e): 560.2 [M<sup>+</sup>-1].

**N**-(2,4-Dinitrophenyl)-4-aminobutyl triphosphate IIc. Yield 30%. UV-VIS (H<sub>2</sub>O, pH 6):  $\lambda_{max}$  265 nm (ε 8300), 363 nm (ε 17500). <sup>1</sup>H-NMR (D<sub>2</sub>O): 9.19 (1H, d, *J*2.8, H3), 8.30 (3H, dd, -5), 7.19 (1H, d, *J*9.65, H6), 3.99 (2H, m, CH<sub>2</sub>), 3.54 (2H, t, *J* 6.8, CH<sub>2</sub>N), 1.82-1.72 (4, m, (CH<sub>2</sub>)<sub>2</sub>). <sup>31</sup>P-NMR (D<sub>2</sub>): -10.10 (1P, d, *J* 19.3, P<sub>γ</sub>), -10.31 (1P, d, *J* 20.3, P<sub>α</sub>), -22.64 (1P, dd, P<sub>β</sub>). Mass (m/e): 494.2 [M<sup>+</sup>-1].

#### REFERENCES

- Arzumanov, A.A.; Victorova, L.S.; Jasko, M.V.; Yesipov, D.S.; Krayevsky, A.A. Terminal deoxynucleotidyl transferase catalyzes the reaction of DNA phosphorylation. *Nucl. Acids Res.* 2000, 28, 1276– 1281.
- Krayevsky, A.A.; Victorova, L.S.; Arzumanov, A.A.; Jasko, M.V. Terminal deoxynucleotidyl transferase catalyzes the reaction of DNA phosphorylation. *Pharmacology and Therapeutics* 2000, 85, 165–173.
- Arzumanov, A.A.; Victorova, L.S.; Jasko, M.V. Synthesis of non-nucleoside triphosphate analogues, a new type of substrates for terminal deoxynucleotidyl transferase. *Nucleosides, Nucleotides & Nucleic* Acids 2000, 19, 1787–1793.
- Khandazhinskaya, A.L.; Jasko, M.V.; Shirokova, E.A.; Kukhanova, M.K. New substrates of terminal deoxynucleotidyl transferase: synthesis and biological evaluation. *Coll. Sympo. Series* 2002, 5, 344–347.
- Khandazhinskaya, A.L.; Kukhanova, M.K.; Jasko, M.V. New Nonnucleoside Substrates for Terminal deoxynucleotidyl transferase: the synthesis and the dependence of substrate properties on structure. *Russ. J. Bioorg. Chem.*, 2005 31, 394–398.
- Crespan, E.; Zanoli, S.; Khandazhinskaya, A.; Shevelev, I.; Jasko, M.; Alexandrova, L.; Kukhanova, M.; Blanca, G.; Villani, G.; Hubscher, U.; Spadari, S.; Maga, G. Incorporation of non-nucleoside triphosphate analogues opposite to an abasic site by human DNA polymerases *β* and *λ*. *Nucl. Acids Res.* 2005, 33, 4117–4127.
- Ludwig, J. Chemical synthesis of nucleoside triphosphates. Acta Biochim. Biophys. Acad. Sci. Hung. 1981, 16, 131–133.
- Crespan E.; Alexandrova L.; Khandazhinskaya A.; Jasko M.; Kukhanova M.; Villani G.; Hubscher U.; Spadari S.; Maga G. Expanding the repertoire of DNA polymerase substrates: template-instructed incorporation of non-nucleoside triphosphate analogues by DNA polymerases β and λ. *Nucleic Acids Res.* 2007, 35, 45–57.